Computational Approaches Drive Developments in Immune-Oncology Therapies for PD-1/PD-L1 Immune Checkpoint Inhibitors

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)
26 Downloads (Pure)

Abstract

Computational approaches in immune-oncology therapies focus on using data-driven methods to identify potential immune targets and develop novel drug candidates. In particular, the search for PD-1/PD-L1 immune checkpoint inhibitors (ICIs) has enlivened the field, leveraging the use of cheminformatics and bioinformatics tools to analyze large datasets of molecules, gene expression and protein–protein interactions. Up to now, there is still an unmet clinical need for improved ICIs and reliable predictive biomarkers. In this review, we highlight the computational methodologies applied to discovering and developing PD-1/PD-L1 ICIs for improved cancer immunotherapies with a greater focus in the last five years. The use of computer-aided drug design structure- and ligand-based virtual screening processes, molecular docking, homology modeling and molecular dynamics simulations methodologies essential for successful drug discovery campaigns focusing on antibodies, peptides or small-molecule ICIs are addressed. A list of recent databases and web tools used in the context of cancer and immunotherapy has been compilated and made available, namely regarding a general scope, cancer and immunology. In summary, computational approaches have become valuable tools for discovering and developing ICIs. Despite significant progress, there is still a need for improved ICIs and biomarkers, and recent databases and web tools have been compiled to aid in this pursuit.
Original languageEnglish
Article number5908
Number of pages28
JournalInternational Journal of Molecular Sciences
Volume24
Issue number6
Publication statusPublished - 21 Mar 2023

Keywords

  • computational methodologies
  • computer-aided drug design (CADD)
  • databases
  • immune checkpoint inhibitor (ICI)
  • immune oncology therapies
  • programmed cell death ligand 1 (PD-L1)
  • programmed cell death protein 1 (PD-1)
  • web tools

Fingerprint

Dive into the research topics of 'Computational Approaches Drive Developments in Immune-Oncology Therapies for PD-1/PD-L1 Immune Checkpoint Inhibitors'. Together they form a unique fingerprint.

Cite this